Geneva Advisors’s GSK GSK Stock Holding History

Geneva Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-4,218	Closed	-$203K	–	794
2016 Q4	$203K	Sell	4,218 -246	-6%	-$12.2K	﹤0.01%	688
2016 Q3	$241K	Buy	+4,464	New	+$245K	﹤0.01%	627

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Geneva Advisors's GSK Position: Q1 2017 in Review

Geneva Advisors sold out of GSK (GSK) in Q1 2017, closing a stake of 4,218 shares — an estimated $203K sold.

Geneva Advisors first reported a position in GSK in Q3 2016 and held it in 2 quarters. The position peaked at $241K in Q3 2016. 787 funds tracked by Wall St. Rank hold GSK as of Q1 2017.

Geneva Advisors reported no remaining GSK position as of Q1 2017 after selling out during the quarter.
Geneva Advisors sold 4,218 GSK shares in Q1 2017, an estimated $203K.
Geneva Advisors first reported a position in GSK in Q3 2016 and held it in 2 quarters.
Geneva Advisors's GSK position peaked at $241K in Q3 2016.
787 funds tracked by Wall St. Rank held GSK as of Q1 2017.

Based on Geneva Advisors's 13F filing for Q1 2017, filed 1 May 2017.